Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to $95.2 million.

  • Pulse Biosciences' Cash & Equivalents rose 2047.37% to $95.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.2 million, marking a year-over-year increase of 2047.37%. This contributed to the annual value of $118.0 million for FY2024, which is 16606.11% up from last year.
  • Pulse Biosciences' Cash & Equivalents amounted to $95.2 million in Q3 2025, which was up 2047.37% from $106.3 million recorded in Q2 2025.
  • Pulse Biosciences' Cash & Equivalents' 5-year high stood at $119.3 million during Q1 2025, with a 5-year trough of $12.7 million in Q1 2022.
  • Its 5-year average for Cash & Equivalents is $59.9 million, with a median of $54.1 million in 2023.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 66148.27% in 2021, then crashed by 7883.21% in 2022.
  • Pulse Biosciences' Cash & Equivalents (Quarter) stood at $44.4 million in 2021, then soared by 37.81% to $61.1 million in 2022, then decreased by 27.44% to $44.4 million in 2023, then surged by 166.06% to $118.0 million in 2024, then decreased by 19.34% to $95.2 million in 2025.
  • Its Cash & Equivalents was $95.2 million in Q3 2025, compared to $106.3 million in Q2 2025 and $119.3 million in Q1 2025.